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DOI 10.1016/j.ccr.2012.05.024SUMMARYKnowledge of oncogenic mutations can inspire therapeutic strategies that are synthetically lethal, affecting
cancer cells while sparing normal cells. Lenalidomide is an active agent in the activated B cell-like (ABC)
subtype of diffuse large B cell lymphoma (DLBCL), but its mechanism of action is unknown. Lenalidomide
kills ABC DLBCL cells by augmenting interferon b (IFNb) production, owing to the oncogenic MYD88 muta-
tions in these lymphomas. In a cereblon-dependent fashion, lenalidomide downregulates IRF4 and SPIB,
transcription factors that together prevent IFNb production by repressing IRF7 and amplify prosurvival
NF-kB signaling by transactivating CARD11. Blockade of B cell receptor signaling using the BTK inhibitor
ibrutinib also downregulates IRF4 and consequently synergizes with lenalidomide in killing ABC DLBCLs,
suggesting attractive therapeutic strategies.INTRODUCTION
The activated B cell-like (ABC) subtype of diffuse large B cell
lymphoma (DLBCL) is much less curable than the other common
DLBCL subtypes—germinal center B cell-like (GCB DLBCL) and
primary mediastinal B cell lymphoma (PMBL)—necessitating
new therapeutic strategies (Alizadeh et al., 2000; Lenz et al.,
2008b; Rosenwald et al., 2002, 2003). ABC DLBCL tumors
have constitutive NF-kB activity, which maintains their viability
(Davis et al., 2001). Additionally, NF-kB induces expression of
IRF4 (Davis et al., 2001; Saito et al., 2007), a key transcription
factor in B cell differentiation and activation (Shaffer et al.,Significance
New therapies are needed for the activated B cell-like (ABC) s
refractory subtype of this lymphoma. Oncogenic mutations
engaging NF-kB and IFNb signaling. Lenalidomide, a drug sh
inducing IFNb and blocking NF-kB. Lenalidomide antagoniz
transcription factors IRF4 and SPIB, which together suppres
to NF-kB induces IRF4 expression in ABC DLBCL. Inhibition
lenalidomide to block IRF4 and kill ABC DLBCL cells, supporti2009). IRF4 binds to a 10-base-pair motif, termed the ETS/IRF
composite element (EICE) (Kanno et al., 2005; Marecki and
Fenton, 2000), in conjunction with one of two highly homologous
ETS-family transcription factors, PU.1 and SPIB (Brass et al.,
1996; Eisenbeis et al., 1995; Shaffer et al., 1997). SPIB is required
for the survival of ABC DLBCL lines and is recurrently amplified
and occasionally translocated in ABC DLBCL, suggesting an
oncogenic function (Lenz et al., 2007, 2008c). IRF4 is required
for the survival of multiple myeloma cells, but its role in ABC
DLBCL has not been addressed (Shaffer et al., 2008).
The molecular basis for constitutive NF-kB activation in ABC
DLBCLwas elucidated using functional and structural genomics.ubtype of diffuse large B cell lymphoma (DLBCL), the most
activate the BCR and MYD88 pathways in ABC DLBCL,
owing clinical activity against DLBCL, kills ABC DLBCLs by
es a central regulatory hub in ABC DLBCL governed by
s IFNb while augmenting NF-kB. Oncogenic BCR signaling
of BCR signaling with the drug ibrutinib synergizes with
ng clinical trials of this synthetically lethal drug combination.
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Figure 1. Lenalidomide Induces a Toxic Type I Interferon Response in ABC DLBCL
(A) Viability (MTS assay) of ABC and GCB DLBCL cell lines treated with lenalidomide for 4 days. Error bars show the SEM of triplicates.
(B) Relative expression of interferon signature genes over a time course of lenalidomide (10 mM) treatment. Gene-expression changes induced by lenalidomide
are depicted according to the color scale shown. Average relative expression of interferon signature genes is at the bottom. Yellow bars, genes with overlapping
IRF4/SPIB ChIP-seq peaks.
Cancer Cell
Synthetic Lethal Therapy of ABC DLBCL
724 Cancer Cell 21, 723–737, June 12, 2012 ª2012 Elsevier Inc.
Cancer Cell
Synthetic Lethal Therapy of ABC DLBCLFollowing BCR engagement, the signaling adaptor CARD11
coordinates the activation of IkB kinase (IKK), a key regulator
of NF-kB signaling (Thome et al., 2010). CARD11 is required
for NF-kB activity and viability of ABC DLBCL lines (Ngo et al.,
2006), and in 10% of ABC DLBCLs, CARD11 acquires onco-
genic mutations leading to spontaneous IKK and NF-kB activity
(Lenz et al., 2008a). In other DLBCLs, BCR signaling engages
wild-type CARD11 to activate NF-kB, a phenomenon termed
chronic active BCR signaling (Davis et al., 2010). More than
20% of ABC DLBCL tumors have mutant forms of the CD79B
and CD79A subunits of the BCR that augment receptor
signaling, establishing the pathogenetic importance of the BCR
pathway in ABC DLBCL (Davis et al., 2010).
The survival of ABC DLBCL lines also depends upon MYD88,
a key adaptor in Toll-like receptor signaling (Ngo et al., 2011).
Oncogenic gain-of-function mutations in MYD88 are among
the most recurrent genetic aberrations in ABC DLBCL (Ngo
et al., 2011). MYD88 promotes NF-kB and JAK/STAT3 signaling,
thereby sustaining ABC DLBCL viability. Additionally, MYD88
mutants induce interferon b (IFNb) production and autocrine
type I interferon signaling, which paradoxically promotes cell-
cycle arrest and apoptosis (Stark et al., 1998).
New therapeutic strategies are being devised to exploit the
separate oncogenic mechanisms in the DLBCL subtypes. A
recent phase 2 clinical trial revealed that lenalidomide is an
active agent in relapsed/refractory DLBCL (Hernandez-Ilizaliturri
et al., 2011). Retrospective analysis showed a 55% response
rate in non-GCB DLBCL (including ABC DLBCL cases) com-
pared with a 9% response rate in GCB DLBCL. More than half
of the responses in non-GCB DLBCL were complete, extending
the progression-free survival of this cohort, although overall
survival remained unchanged. In the present study, we investi-
gated the molecular mechanisms underlying the toxicity of
lenalidomide for ABC DLBCL cells in order to design rational
strategies to optimize its therapeutic effect.
RESULTS
Lenalidomide Induces a Lethal Type I Interferon
Response in ABC DLBCL
To understand the molecular basis for the efficacy and speci-
ficity of lenalidomide in treating lymphoma, we assessed its
effect on the viability of cell line models of DLBCL. Lenalidomide
treatment was toxic to most ABC DLBCL cell lines, whereas
most GCB DLBCL lines were unaffected (Figure 1A). To in-
vestigate the mechanisms of this toxicity, we profiled gene-
expression changes in ABC DLBCL lines upon exposure to
lenalidomide (Figure 1B). Lenalidomide increased the expression(C and D) IFNb mRNA expression and secretion in lenalidomide-treated (10 mM)
(E) Activity of an ISRE-driven luciferase reporter in cells treated with lenalidomide
SEM of triplicates.
(F) Western blot analysis of the indicated proteins in lenalidomide-treated (10 mM
(G) Viability (MTS assay) of DLBCL cells treated with the indicated amount of hu
(H) Measurement of viability (MTS assay; right) and apoptosis (PARP cleavage an
compounds (DMSO or isotype-matched antibody), lenalidomide (1 mM), or lenalid
show the SEM of triplicates.
(I) Viability (MTS assay) of OCI-Ly10 ABC DLBCL cells in which the indicated shR
indicated, for 4 days. Error bars show the SEM of triplicates.
See also Figure S1 and Table S1.of 476 genes and reduced the expression of 272 genes (Tables
S1F and S1G, available online). To gain biological insight into
these lenalidomide-responsive genes, we used a database of
gene-expression signatures that reflect signaling and regulatory
processes in normal and malignant cells (Shaffer et al., 2006).
The most consistent signatures upregulated by lenalidomide
were those associated with the type I interferon response
(Table S1A; Figure 1B). Conversely, signatures of NF-kB, JAK,
and MYD88 signaling were downregulated by lenalidomide
(Table S1B), suggesting that blockade of these prosurvival path-
ways contributes to lenalidomide toxicity (see below).
Lenalidomide increased interferon b (IFNb) mRNA expression
and protein secretion in themajority of ABC DLBCL lines, but not
in most other DLBCL lines (Figures 1B–1D). In ABC DLBCL lines,
lenalidomide activated a reporter gene driven by an interferon-
stimulated response element (ISRE), which did not occur in
GCB DLBCL lines, even though they respond to exogenously
added interferon (Figures 1E and S1B). Moreover, the drug
induced phosphorylation of TYK2, a JAK-family kinase associ-
ated with the type I interferon receptor, and STAT1, a transcrip-
tion factor that is phosphorylated by TYK2 (Figure 1F).
Addition of IFNb to cultures of ABC DLBCL lines induced cell
death, with a potency that paralleled the effect of lenalidomide,
suggesting that IFNb might contribute to lenalidomide toxicity
(Figures 1G and S1A). Indeed, antibodies against the interferon
a/b receptor chain 2 (anti-IFNAR2) or IFNb inhibited lenalido-
mide-induced death (Figure 1H). Likewise, silencing of the
interferon a/b receptor chain 1 (IFNAR1) or TYK2 by RNA interfer-
ence reduced lenalidomide toxicity (Figures 1I, S1C, and S1I).
Moreover, lenalidomide-induced STAT1 phosphorylation was
blunted by anti-IFNAR2 antibodies or by IFNAR1 knockdown
(Figure S1D).
Apoptosis induced by interferon is associatedwith induction of
TRAIL (Oshima et al., 2001; Ucur et al., 2003). TRAIL (TNFSF10)
mRNA and protein levels were increased by lenalidomide in ABC
DLBCL cells and anti-IFNAR2 antibodies blocked this induction
(Figures 1B and S1E–S1G). Anti-TRAIL antibodies partially
rescued ABC DLBCL cells from lenalidomide-induced death
(Figure S1H), suggesting that TRAIL induction contributes to
lenalidomide toxicity but is not the only cell-death mechanism
involved (see below).
The IRF4 and SPIB Regulatory Network in ABC DLBCL
In a separate initiative, we defined the gene network controlled
by the transcription factor IRF4, allowing us to appreciate
an unexpected regulatory connection between IRF4 and lenali-
domide. IRF4 expression is a hallmark of ABC DLBCL, sec-
ondary to the constitutive NF-kB activation and plasmacyticcells. Error bars show the SEM of triplicates.
(10 mM) or vehicle control (DMSO) at the indicated times. Error bars show the
) ABC DLBCL cells.
man recombinant IFNb for 4 days. Error bars show the SEM of triplicates.
d caspase-3 activation by FACS; left) in ABC DLBCL cells treated with control
omide plus the indicated blocking antibodies (2.5 mg/ml) for 4 days. Error bars
NAs were induced for 2 days before treatment with DMSO or lenalidomide, as
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Figure 2. IRF4 and SPIB Are Required for ABC DLBCL Viability
(A) Toxicity of an IRF4 shRNA in a loss-of-function RNA interference screen of the indicated cell lines. Shown are the log2 ratios of shRNA abundance before
induction (uninduced d0) versus abundance after 21 days in culture (induced d21). shRPS13 targets ribosomal protein S13, an essential gene in all cell types. Error
bars show the SEM for quadriplicates.
(B) Viability of shIRF4+ (GFP+) cells over time after induction as a percentage of live shIRF4+ cells following shIRF4 induction relative to day 0. The number of
replicate infections is shown in parentheses. Error bars represent the SEM of replicates.
(C) Overlap of IRF4 ChIP-Seq peaks in ABCDLBCL andmultiple myeloma, based on all peaks (left), genes with an IRF4 peak within ±2 kb of the TSS (middle), and
genes with an IRF4 peak in a region encompassing the gene body and 10 kb upstream of the TSS (right).
(D) Motif discovery using theWeeder andMEME algorithms based on the top 1,000 ABC DLBCL IRF4 ChIP-Seq peaks by sequence tag abundance. The highest
scoring motif is shown with core recognition motifs indicated.
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Synthetic Lethal Therapy of ABC DLBCLdifferentiation that characterizes this subtype (Alizadeh et al.,
2000; Lam et al., 2005; Saito et al., 2007; Wright et al., 2003).
Previously, we demonstrated that all multiple myeloma cell lines
depend on IRF4 for survival (Shaffer et al., 2008). In a focused
RNA interference screen, we observed that IRF4 knockdown
was toxic to both ABC DLBCL and multiple myeloma lines, but
not to a variety of other lymphoma and leukemia lines (Figure 2A;
Table S2A). However, all cell lines were killed comparably when
ribosomal or proteasomal proteins were knocked down. In
confirmatory experiments, induction of an IRF4 shRNA killed
ABC DLBCL and multiple myeloma cells in a time-dependent
fashion, but GCB DLBCL lines were not affected (Figure 2B; Fig-
ure S2H). The toxicity of the IRF4 shRNA was reversed by
ectopic expression of an IRF4 cDNA, confirming its specificity
(Figure S2A). IRF4 mRNA and protein levels were reduced by
40%–60% by this shRNA, indicating that the ABC DLBCL lines
are sensitive to partial IRF4 knockdown (Figure S2B). The cell
cycle was not affected by IRF4 knockdown, but an increase in
cells with sub-G1 DNA content was evident, indicating cell death
(Figure S2C). IRF4 knockdown activated caspase-3, suggesting
that apoptosis was initiated (Figures S2D and S2E), but a
caspase inhibitor did not alter the kinetics of ABC DLBCL cell
death (Figures S2F and S2G), suggesting that nonapoptotic
cell-death mechanisms are also invoked (Shaffer et al., 2008).
To identify genes directly regulated by IRF4, we per-
formed chromatin immunoprecipitation (ChIP) followed by high
throughput DNA sequencing (ChIP-seq) in cell line models of
ABC DLBCL (HBL1) and multiple myeloma (KMS12), as well as
in a GCB DLBCL line that does not express IRF4 (OCI-Ly19).
We identified significant binding events (‘‘peaks’’; see Supple-
mental Experimental Procedures) in HBL1 and KMS12 that
were not present in OCI-Ly19 (Figure 2C), and observed that
IRF4 peaks were enriched near transcription start sites (TSSs)
of protein-coding genes (Figure S2I). We confirmed the presence
of 10 IRF4 binding sites in ABC DLBCL by conventional ChIP
(Figure S2J).
Among IRF4 peaks in the ABC DLBCL line, 3,673 (11%) coin-
cided with IRF4 peaks in the multiple myeloma line (Figure 2C).
We defined a ‘‘whole gene’’ window from 10kb relative to the
TSS and extending through the body of the gene, and observed
that 2,112 genes had IRF4 peaks within this window in both ABC
DLBCL and multiple myeloma (Figure 2C; Tables S2B and S2C).
However, a substantial fraction (>60%) of the IRF4 target genes
in these ABC DLBCL and multiple myeloma cell lines were
unique to each tumor. For example, we previously identified
a positive feedback loop between IRF4 and MYC in multiple
myeloma cells whereby each factor binds the other’s promoter
and drives expression (Shaffer et al., 2008). The IRF4 ChIP-Seq(E) Enrichment for the EICEmotif in promoter-proximal peaks (±2 kb from the TSS)
a function of peak percentile, ranked by sequencing tag abundance.
(F) Overlap of IRF4 and SPIB ChIP-seq peaks in ABC DLBCL, as in (C).
(G) Crystal structure of the mouse IRF4 and PU.1 DNA binding domains interactin
IRF4 and SPIB.
(H) Rescue experiment showing the viability of the indicated cell lines bearing em
fraction of shIRF4+ (GFP+) cells at times following shIRF4 induction relative to d
(I) Rescue experiment as in (H) with cells bearing the indicated SPIB expression
(J) Viability (FACS for live cells) of the indicated cell lines expressing an induc
repressor+ cells relative to empty vector-bearing control cells, at various times f
See also Figure S2 and Table S2.data confirmed IRF4 binding to the MYC locus in multiple
myeloma but not ABC DLBCL (Figure S2K), despite high MYC
expression in ABC DLBCL (Shaffer et al., 2006). IRF4 was itself
an IRF4 target gene in multiple myeloma, suggesting positive
autoregulation, but not in ABC DLBCL (Figure S2K). Conversely,
many genes, such as CD44 and CD40, were bound by IRF4 in
ABC DLBCL but not in multiple myeloma (Figure S2K). These
data suggest distinct IRF4 regulatory networks in these two
malignancies, but analysis of more cell lines will be needed to
fully elucidate these differences.
Using de novo DNA motif discovery algorithms, the most
common sequence in ABC DLBCL IRF4 peaks was an exact
match to the EICE motif (Figure 2D; Table S2D). IRF4 peaks in
multiple myeloma were enriched not for this motif but rather
for a direct repeat of an IRF binding site (GAAT(G/C)GAAT;
Table S2D). Among promoter-proximal peaks, EICE enrichment
steadily increased as a function of IRF4 peak intensity in ABC
DLBCL (p = 1.81E-24) and was located near the point of highest
ChIP-seq intensity within each peak (Figures 2E and S2L). These
data imply that IRF4 binds with an ETS family member to the
EICE motif in ABC DLBCL but relies on other mechanisms to
interact with its target genes in multiple myeloma.
IRF4 binds to the EICE motif with either PU.1 or SPIB, neither
of which is expressed inmyeloma cells. SPIB is characteristically
expressed in ABC DLBCL and can be further upregulated by
amplification or translocation of its genomic locus (Lenz et al.,
2007, 2008c). Given that ABC DLBCL lines require SPIB for
survival (Lenz et al., 2008c), we suspected that SPIB was the
relevant IRF4 binding partner in these cells. To perform ChIP-
seq for SPIB, we engineered the HBL1 ABC DLBCL line to
express biotinylated SPIB (SPIB biotag; see Experimental
Procedures). SPIB peaks were found preferentially near TSSs
in ABC DLBCL (Figure S2M), and were enriched for the ETS-
family DNA-binding motif (GGAA; Table S2D). SPIB and IRF4
peaks in ABC DLBCL overlapped 4.3-fold more often than ex-
pected by chance (p < 10E-300) (Figure 2F, Tables S2E and
S2F). EICE motifs within IRF4 and SPIB binding peaks were
enriched near TSSs (p = 1.91E-135) and their frequency
increased as a function of peak intensity (Figures 2E, S2L, and
S2M). Overlapping IRF4-SPIB peakswere present at 3610 genes
in ABC DLBCL, with 33% of those peaks containing at least one
EICE (Table S2F).
The dependence of ABC DLBCLs on IRF4 and SPIB predicted
that disruption of the IRF4-SPIB interaction would be deleterious
to ABC DLBCL viability. A crystal structure of the mouse IRF4
and PU.1 DNA binding domains bound to an EICE motif allowed
us to model the human IRF4-SPIB interaction (Escalante et al.,
2002a, 2002b). IRF4 contacts PU.1 across the DNA minorbased on IRF4 and SPIBChIP-Seq data in ABCDLBCL ormultiplemyeloma, as
g with an EICE, showing the interacting charged residues conserved in human
pty vector, wild-type IRF4, or mutant IRF4 expression vectors, plotted as the
ay 0.
vectors and an inducible SPIB-30UTR-targeted shRNA.
ible IRF4-SPIB chimeric repressor, plotted as a percentage of live chimeric
ollowing chimeric repressor induction.
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Figure 3. IRF4 Controls Essential Gene-Expression Programs in ABC DLBCL
(A) IRF4 direct target genes grouped according to gene-expression signatures (Shaffer et al., 2006). Signatures with significant enrichment for IRF4 targets were
grouped by function (Table S3A). Genes that are induced or repressed by IRF4 are indicated in green and red, respectively. Asterisks indicate genes with an
overlapping IRF4-SPIB ChIP-seq peak.
(B) ISRE-driven luciferase reporter activity in ABC DLBCL lines with control or IRF4 shRNAs after 2 days of induction and subsequent addition of IFNb (1,000 U).
Error bars show the SEM of triplicates.
See also Figure S3 and Table S3.
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Synthetic Lethal Therapy of ABC DLBCLgroove via charged residues that are conserved in human
IRF4 (aspartic acid 117) and human SPIB (arginine 219 and
lysine 220) (Figure 2G). We generated IRF4 and SPIB mutants
to test whether this protein-protein interface is essential for
ABC DLBCL survival. As expected, ectopic expression of the
wild-type IRF4 coding region rescued ABC DLBCL and multiple
myeloma lines from the toxicity of a 30UTR-directed IRF4
shRNA, whereas an IRF4 DNA-binding mutant was inactive (Fig-
ure 2H). IRF4 interaction mutants with histidine or alanine at
position 117 were expressed as efficiently as wild-type IRF4
and were not toxic (data not shown), but did not sustain ABC
DLBCL viability (Figure 2H). By contrast, these mutants did
rescue multiple myeloma cells from IRF4 shRNA toxicity,
demonstrating that they are functional in this context. Wild-
type SPIB was able to rescue ABC DLBCL cells from SPIB
knockdown, but SPIB interaction mutants with alanine or glycine
substitutions at positions 219 and 220 were ineffective, while
being equivalently expressed and nontoxic (Figure 2I; data not
shown).
This mutational analysis indicated that the IRF4-SPIB interac-
tion is critical for ABC DLBCL viability. To test this further, we
created a fusion protein between the DNA binding domains of
IRF4 and SPIB based on previous work showing that an IRF4-
PU.1 fusion functions as a sequence-specific transcriptional
repressor (Brass et al., 1999). The IRF4-SPIB chimeric protein728 Cancer Cell 21, 723–737, June 12, 2012 ª2012 Elsevier Inc.was acutely toxic to ABC DLBCL but not to GCB DLBCL lines
(Figure 2J, and see below). This chimeric repressor was not toxic
to IRF4-dependent multiple myeloma lines, suggesting that it
specifically represses genes that require both IRF4 and SPIB
for expression.
Pathways Regulated by IRF4-SPIB in ABC DLBCL
To determine the nature of the genes and pathways controlled by
IRF4 and SPIB in ABC DLBCL, we profiled gene-expression
changes upon IRF4 knockdown, allowing us to define a set of
genes that were consistently downregulated (n = 435) or upregu-
lated (n = 410) (Tables S3G and S3H; Figure S3A). Many of these
genes were similarly regulated by SPIB and the chimeric IRF4-
SPIB repressor (Tables S3I, S3J, and S3K). For example, among
the downregulated genes, 46% and 42% also decreased in
expression following SPIB knockdown and IRF4-SPIB chimeric
repressor induction, respectively. Among IRF4-regulated genes,
we defined ‘‘direct targets’’ as those that had an IRF4 binding
peak within the whole-gene window specified above (Figure 2C).
Many IRF4 direct targets had overlapping IRF4-SPIB peaks
(Figure 3A).
Gene-expression signatures that were enriched among IRF4
targets were those that distinguish the DLBCL subtypes, charac-
terize hematopoietic differentiation states, or are regulated by
signaling pathways active in ABC DLBCL (Figure 3A; Table S3).
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Figure 4. Lenalidomide Toxicity in ABC DLBCL is Opposed by IRF4 and SPIB
(A and C) Western blot of IRF4, SPIB, and b-actin proteins in ABC DLBCL cell lines treated with lenalidomide (10 mM) over time.
(B and D) IRF4 and SPIBmRNA expression quantified byQ-PCR, normalized to b2-microglobulin (B2M) expression, in the ABCDLBCL line OCI-Ly10 treatedwith
lenalidomide (10 mM). Error bars show the SEM of triplicates.
(E and F) IFNbmRNA expression and protein secretion in the OCI-Ly10 ABCDLBCL line induced for IRF4 or control shRNA expression for 2 days and treated with
lenalidomide (10 mM). Error bars represent the SEM of triplicates.
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Synthetic Lethal Therapy of ABC DLBCLAmong IRF4 upregulated genes, a signature of genes more
highly expressed in ABC DLBCL than GCB DLBCL was the
most enriched (ABCDLBCL-4, p = 1.18E-18). Represented are
genes that specify the cell-surface phenotype of ABC DLBCL
(CD44, ENTPD1, IL10RA), as well as genes encoding important
regulatory proteins, notably CARD11 (see below). Conversely,
among IRF4 downregulated genes, a signature of genes more
highly expressed in GCB DLBCL than ABC DLBCL was enriched
(GCBDLBCL-3, p = 3.84E-5). IRF4 upregulated genes also
included genes more highly expressed in plasma cells than in
mature B cells (PC-2, p = 2.33E-08), in keeping with the essential
role of IRF4 in plasmacytic differentiation (Klein et al., 2006;
Sciammas et al., 2006). A signature of plasmacytoid dendritic
cells was also enriched among IRF4 upregulated genes (DC-4,
p = 1.53E-08), consonant with the role of IRF4 in the dif-
ferentiation of this lineage (Lehtonen et al., 2005; Schotte et al.,
2003; Tamura et al., 2005).
Prominent among IRF4 direct targets were genes regulated by
key ABC DLBCL signaling pathways. A signature of NF-kB acti-
vation was enriched among genes that were upregulated by IRF4
(NFKB-10, p = 1.38E-17; Figure 3A). As discussed above, this
NF-kB signature was downregulated by the treatment of ABC
DLBCLs with lenalidomide (Table S1). Signatures that reflect
autocrine IL-10 and/or IL-6 signaling in ABC DLBCL cells were
enriched among genes that were repressed by IRF4, suggesting
that IRF4 dampens JAK/STAT3 signaling in ABC DLBCL
(IL10Up-1, p = 1.83E-15; IL6Up-4, p = 2.23E-11; Figure 3A;
Table S3) (Lam et al., 2008). Finally, a signature of type I inter-
feron signaling was significantly represented among IRF4-
repressed target genes (IFN-3, p = 5.80E-06; Figure 3A, Table
S3). These interferon signature genes were induced by lenalido-
mide treatment of ABC DLBCL cells, and many of these induced
genes had IRF4-SPIB intersection peaks (Figure 1B). Accord-
ingly, IRF4 knockdown in ABC DLBCL lines increased their
response to exogenous IFNb, as measured by an ISRE reporter
(Figures 3B and S3B).(G) Western blot of the indicated proteins in OCI-Ly10 following induction of IRF4
indicated times.
(H) ISRE-driven luciferase reporter activity in OCI-Ly10 with control or IRF4 shR
triplicates.
(I) TRAIL mRNA quantified by Q-PCR, normalized to B2M, in OCI-Ly10 cells with s
times. Error bars show the SEM of triplicates.
(J) Western blot analysis of the indicated proteins in OCI-Ly10 cells transduced wit
48 hr, then treated with lenalidomide (10 mM) for the indicated times. The lower IRF
(K) Viability of ABC DLBCL lines induced to express control, IRF4, or SPIB shR
induction. See text for details.
(L) Viability of OCI-Ly10 cells transduced with an IRF4 expression or empty vector,
bars represent the SEM of triplicates.
(M) Viability (MTS assay) of OCI-Ly10 cells induced to express the indicated shRN
4 days. ctrl.,control. Error bars show the SEM of triplicates.
(N) IFNb mRNA expression, measured by Q-PCR, in OCI-Ly10 cells induced to e
indicated times. Error bars show the SEM of triplicates.
(O) TMD8 ABC DLBCL cells expressing an IkBa-luciferase fusion protein were
lenalidomide at the indicated concentrations or DMSO for 2 days. Luciferase activi
with the IKKb inhibitor MLN120B (10 mM) for 2 days. Error bars show the SEM o
(P) IRF4 and SPIB mRNA expression, quantified by Q-PCR, in TMD8 cells trans
followed by lenalidomide treatment (10 mM) for 24 hr. Error bars show the SEM o
(Q) Western blot for the indicated proteins in TMD8 cells induced to express CRBN
for 24 hr.
See also Figure S4.
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This signature analysis suggested that IRF4 and SPIB cooperate
to modulate type I interferon and NF-kB signaling in ABC DLBCL
in a manner opposite to their regulation by lenalidomide. We
therefore wondered if lenalidomide might have a direct effect
on IRF4 or SPIB expression in ABC DLBCL. Indeed, IRF4 and
SPIB mRNA and protein levels dropped rapidly upon lenalido-
mide treatment of ABC DLBCL cells (Figures 4A–4D), suggesting
that lenalidomide affects the expression of IRF4 and SPIB target
genes by decreasing the levels of both factors.
Given that lenalidomide only reduced IRF4 expression
partially, we tested whether further silencing of IRF4 by RNA
interference would enhance the interferon response in ABC
DLBCL cells. Induction of IFNbmRNA expression and secretion
by lenalidomide was augmented by IRF4 knockdown (Figures 4E
and 4F). IRF4 knockdown also increased lenalidomide-induced
STAT1 phosphorylation, ISRE promoter activity, and TRAIL
upregulation (Figures 4G–4I). Conversely, ectopic expression
of IRF4 suppressed lenalidomide-induced STAT1 phosphoryla-
tion (Figure 4J).
We next tested whether expression of IRF4 and SPIB in ABC
DLBCL interferes with the toxicity of lenalidomide. We infected
cells with vectors that expressed IRF4 or SPIB shRNAs along
with green fluorescent protein (GFP), allowing us to visualize
the subpopulation of cells that had been transduced with the
shRNA. By comparing the viability of shRNA-transduced
(GFP+) and shRNA-nontransduced (GFP–) cells, which were
equally exposed to lenalidomide, we could discern how IRF4 or
SPIB knockdown influenced lenalidomide toxicity. In the
absence of lenalidomide, knockdown of IRF4 or SPIB alone
was toxic for ABC DLBCLs, as expected (Figure 4K). The
addition of lenalidomide accelerated the loss of cells bearing
IRF4 and SPIB shRNAs relative to those bearing a control
shRNA (Figure 4K). Conversely, ectopic expression of IRF4 coun-
teracted lenalidomide toxicity in ABC DLBCL (Figure 4L). Also,or control shRNAs for 2 days and treatment with lenalidomide (10 mM) for the
NAs after lenalidomide (10 mM) treatment. Error bars represent the SEM of
hRNA induction for 2 days and lenalidomide (10 mM) treatment for the indicated
h a flag epitope-tagged IRF4 expression vector or an empty vector, induced for
4 band is endogenous IRF4; the upper band is FLAG-tagged exogenous IRF4.
NAs and treated with DMSO or lenalidomide (10 mM) over a time course of
induced for 24 hr, and then treated with DMSO or lenalidomide for 4 days. Error
As for 2 days and treated with lenalidomide at the indicated concentrations for
xpress CRBN shRNAs for 2 days and treated with lenalidomide (10 mM) for the
induced to express control or CRBN shRNAs for 2 days, then treated with
ty was normalized to the DMSO control. As a positive control, cells were treated
f triplicates.
duced with the indicated shRNAs. shRNA expression was induced for 2 days
f triplicates.
or control shRNAs for 2 days, followed by treatment with lenalidomide (10 mM)
A B C D
E F G H
Figure 5. IRF4-SPIB Block Interferon Signaling by Repressing IRF7
(A) UCSCbrowser depiction of ChIP-seq data fromHBL1ABCDLBCL cells showing IRF4 and SPIB-biotag binding at the IRF7 promoter. Arrow indicates the TSS.
(B) IRF4 binding at the IRF7 locus by ChIP in OCI-Ly10 ABC DLBCL cells treated with DMSO (–) or lenalidomide (10 mM) for 24 hr. Error bars show SEM of
triplicates.
(C) Q-PCR quantification of IRF7 mRNA levels, normalized to B2M, in OCI-Ly10 cells with control (ctrl.) or IRF4 shRNAs, treated with lenalidomide (10 mM) or
DMSO. Error bars show SEM of triplicates.
(D) Western blot of the indicated proteins in cells from (C).
(E) Viability (MTS assay) of OCI-Ly10 cells induced to express the indicated shRNAs for 2 days and then treated with DMSO or lenalidomide (10 mM) for 4 days.
Error bars show SEM of triplicates.
(F) Western blot of the indicated proteins in ABC DLBCL lines induced to express control or IRF7 shRNAs for 2 days and then treated with DMSO or lenalidomide
(10 mM) for the indicated times.
(G and H) Q-PCR analysis, normalized to B2M, of IFNb (G) or TRAIL (H) mRNA levels in OCI-Ly10 cells induced to express control or IRF7 shRNAs for 2 days and
treated with DMSO (–) or lenalidomide (10 mM; +) for 24 hr. Error bars show SEM of triplicates.
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induced IFNb expression and increased lenalidomide toxicity
(Figures S5F and S5G). Hence, IRF4 and SPIB regulate
lenalidomide-induced interferon responses and toxicity in ABC
DLBCL.
Cereblon Mediates the Toxic Effect of Lenalidomide
in ABC DLBCL
Recent studies have demonstrated that the activity of thalido-
mide and lenalidomide is mediated by cereblon (CRBN), a
component of a ubiquitin-ligase complex (Ito et al., 2010; Zhu
et al., 2011). To address whether CRBN is required for the toxic
effects of lenalidomide in ABC DLBCL, we identified three
shRNAs that reduced CRBN mRNA expression by 50% (Fig-
ure S4A). CRBN knockdown was moderately toxic for ABC
DLBCL cells (Figure S4C), an effect that was reversed by ectopic
expression of CRBN. CRBN depletion substantially reduced the
toxicity of lenalidomide for ABC DLBCL cells (Figures 4M, S4B,
and S4C) and interfered with the ability of lenalidomide to induce
an interferon response and block NF-kB signaling (Figures 4N,
4O, S4D, and S4E). CRBN depletion lowered IRF4 mRNA and
protein levels in ABCDLBCL cells and reduced the effect of lena-
lidomide on IRF4 levels (Figures 4P, 4Q, and S4F). Similarly, SPIB
mRNA and protein levels were also diminished upon CRBNknockdown (Figures 4P and 4Q). Thus, CRBN is required to
maintain IRF4 and SPIB levels in ABC DLBCL, accounting for
the toxicity of CRBNdepletion. Moreover, these findings suggest
that CRBN mediates most of the effects of lenalidomide in ABC
DLBCL.
IRF4 Represses the Interferon Pathway by Inhibiting
IRF7 Expression
We noted that three IRF family member genes that regulate the
type I interferon responses—IRF2, IRF7, and IRF9—were bound
by IRF4 and SPIB (Table S3F). We focused on a strong IRF4-
SPIB peak in the promoter of the IRF7 gene (Figure 5A), since
it is a master regulator of interferon responses that is strongly
induced by IFNb as part of a positive-feedback loop (Honda
et al., 2005; Marie´ et al., 1998; Sato et al., 1998). Binding of
IRF4 to the IRF7 promoter was confirmed by an independent
ChIP assay, and lenalidomide reduced this binding (Figure 5B).
IRF7mRNA and protein were specifically induced in ABCDLBCL
by lenalidomide and were further induced by knocking down
IRF4 (Figures 5C and 5D). Together, these results suggest that
IRF7 is negatively regulated by IRF4 and SPIB, and that lenalido-
mide can blunt this negative regulation.
We next examined whether IRF7 expression is important
for the toxicity of lenalidomide in ABC DLBCL cells. IRF7Cancer Cell 21, 723–737, June 12, 2012 ª2012 Elsevier Inc. 731
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Figure 6. IRF4-SPIB and CARD11 Form an Essential Oncogenic Loop in ABC DLBCL
(A) UCSC browser depiction of ChIP-seq data from the HBL1 ABC DLBCL line showing IRF4 (in triplicate) and SPIB-biotag binding at the CARD11 locus, with an
evolutionarily conserved EICE binding motif indicated. Control (IRF4): OCI-Ly19 (IRF4-). Control (SPIB): HBL1 with empty biotag vector. Arrow indicates the TSS.
(B) ChIP analysis in HBL1 cells for IRF4 and SPIB binding at the CARD11 peak identified in (A) or at a negative control (ctrl.) locus. IRF4 or control shRNAs were
induced for 4 days. GCB DLBCL line: OCI-Ly19 (IRF4-) is IRF4-negative. Error bars show SEM of triplicates.
(C) Relative CARD11 mRNA expression, depicted according to the color scale shown, from gene-expression profiling of ABC DLBCL lines after induction of
shIRF4 or the IRF4-SPIB chimeric repressor for 4 days.
(D) IKK activity measured by an IkBa-luciferase reporter in TMD8 (ABC DLBCL) after induction of various shRNAs for 3 days (left) or the IRF4-SPIB chimeric
repressor for 1 day (right). Also shown is the effect of 1 day exposure to an IKKb inhibitor (MLN120B) or DMSO. Error bars show SD of triplicates.
(E) Western blot analysis of the indicated proteins following treatment of OCI-Ly10 cells with lenalidomide (10 mM) for the indicated times.
(F) IKK activity measured by an IkBa-luciferase reporter after treatment of TMD8 cells with lenalidomide at the indicated concentrations for 48 hr. Error bars show
the SEM of triplicates.
See also Figure S5.
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DLBCL cells (Figure 5E). IRF7 depletion additionally impaired
lenalidomide-induced STAT1 phosphorylation, IFNb expression,
and TRAIL mRNA induction (Figures 5F–5H). Hence, IRF7 pro-
motes lenalidomide toxicity by facillitating lenalidomide-induced
IFNb secretion and signaling.
IRF4-SPIB and CARD11 Form an Essential Oncogenic
Loop in ABC DLBCL
While treatment with lenalidomide induces a toxic interferon
response in ABC DLBCLs, blocking interferon signaling did not
fully rescue the cells. We therefore wondered if there might be
other mechanisms by which lenalidomide kills these lymphoma
cells. Given that ABC DLBCL cells depend upon the NF-kB
pathway for survival (Davis et al., 2001; Lam et al., 2005) and
that lenalidomide suppressed the NF-kB gene-expression
signature (Table S1), we hypothesized that decreased NF-kB732 Cancer Cell 21, 723–737, June 12, 2012 ª2012 Elsevier Inc.signaling contributes to the toxicity of lenalidomide in ABC
DLBCL cells.
Since lenalidomide downregulates IRF4 and SPIB (Figures 4A
and 4B), we were intrigued that CARD11 was a direct IRF4 and
SPIB target (Figure 3A, Tables S2B, S2E, and S2F). CARD11
plays an essential role in the constitutive NF-kB activity that
maintains ABC DLBCL viability (Davis et al., 2001; Lam et al.,
2005; Ngo et al., 2006). The CARD11 locus had prominent,
overlapping IRF4 and SPIB binding peaks located +705 bp rela-
tive to the TSS, coinciding with an evolutionarily conserved
EICE motif (Figure 6A). IRF4 and SPIB binding was confirmed
by independent ChIP assays, and IRF4 knockdown diminished
this binding (Figure 6B). Gene-expression profiling and quanti-
tative PCR analysis showed that CARD11 mRNA levels are
diminished by knockdown of IRF4 or SPIB, as well as by ex-
pression of the IRF4-SPIB chimeric repressor (Figures 6C
and S5A). CARD11 protein levels were also reduced after
Cancer Cell
Synthetic Lethal Therapy of ABC DLBCLIRF4 knockdown or chimeric repressor induction (Figure S5B
and S5C).
Since CARD11 coordinates the activation of IKK (Thome,
2004), the key regulatory kinase in the classical NF-kB pathway,
we assessed IKK function using an ABC DLBCL reporter line
engineered to express a fusion protein between luciferase and
the IKK substrate IkBa (Lam et al., 2005). Phosphorylation of
this fusion protein by IKK promotes its degradation, and thus
IKK inhibition increases luciferase activity. Knockdown of either
IRF4 or SPIB reduced IKK activity in the ABC DLBCL line TMD8,
as did CARD11 knockdown or treatment with a small molecule
IKK inhibitor, but two other toxic shRNAs targeting MYC and
RPL6 did not (Lam et al., 2005) (Figure 6D). Moreover, induction
of the chimeric IRF4-SPIB repressor also inhibited IKK activity
(Figure 6D). Similar results were observed in an ABC DLBCL
line, OCI-Ly3, that relies on an oncogenically active CARD11
mutant for survival (Lenz et al., 2008a), in keeping with an effect
of IRF4 and SPIB on CARD11 transcription (Figure S5H). In
accord with these functional experiments, knockdown of IRF4
decreased IKKb phosphorylation, a modification associated
with IKK activation downstream of CARD11 (Figure S5E). The
effect of IRF4 on the NF-kB pathway was confirmed using an
independent ABC DLBCL reporter system in which luciferase
is driven by an NF-kB-dependent promoter (Figure S5D).
Lenalidomide treatment of an ABC DLBCL line reduced
CARD11 expression and IKKb phosphorylation, and inhibited
IKK activity (Figures 6E and 6F). Together, these data suggest
that IRF4 and SPIB act together to amplify NF-kB signaling in
ABC DLBCL by transactivating CARD11 and that lenalidomide
inhibits NF-kB by downregulating IRF4 and SPIB, breaking this
positive feed-forward loop.
Synergism between Lenalidomide and NF-kB Pathway
Inhibitors
Since lenalidomide only partially inhibits IRF4 and SPIB expres-
sion (Figures 4A–4D), we speculated that we could achieve
greater toxicity by additionally blocking IKK, thereby further
reducing NF-kB-dependent IRF4 expression. The IKKb inhibitor
MLN120B selectively kills ABC DLBCL cells, as does ibrutinib,
a BTK kinase inhibitor that blocks signaling from the BCR to
IKK (Davis et al., 2010; Lam et al., 2005). Treatment of ABC
DLBCL cells with either MLN120B or ibrutinib alone decreased
IRF4 protein levels, but when these agents were combined
with lenalidomide, IRF4 became undetectable (Figure 7A). The
combination of ibrutinib and lenalidomide induced a stronger
interferon response than lenalidomide alone, as measured by
ISRE reporter activity and STAT1 phosphorylation (Figures 7A
and 7B). These two drugs also cooperated in blocking IKK
activity (Figure 7C).
To test for synergistic toxicity, an ABC DLBCL line was treated
with the MLN120B at a range of doses that were only modestly
toxic, in the presence or absence of low dose lenalidomide.
The ABCDLBCL cells were killedmore efficiently with the combi-
nation of these drugs than with either drug alone (Figure 7D).
Similarly, synergistic toxicity was observed in ABC DLBCL lines
when lenalidomide and ibrutinib were combined, but no toxicity
was observed in GCB DLBCL lines that lack oncogenic activa-
tion of the BCR and MYD88 pathways (Figures 7E and S6A). A
formal mathematical algorithm (Greco et al., 1990) confirmedthe strong synergism between ibrutinib and lenalidomide in
killing three ABC DLBCL lines (Figure S6B). Finally, we tested
this drug combination in a xenograft mouse model created using
the OCI-Ly10 ABC DLBCL cell line (Figures 7F and S6C). At the
concentrations of lenalidomide and ibrutinib chosen, both drugs
had little effect on the growth of the xenografts as single agents
(Figures 7F and S6C) but were quite effective in combination in
arresting the growth of established tumors.
DISCUSSION
New treatments for ABC DLBCL should ideally exploit emerging
insights into oncogenic pathways, which create opportunities for
synthetic lethal interactions with drugs that target these path-
ways (Figure 8). The BCR and MYD88 signaling pathways
promote ABCDLBCL viability by inducingNF-kB, and both path-
ways are affected by recurrent oncogenic mutations in ABC
DLBCL.However, thepenalty that ABCDLBCLspayby acquiring
oncogenic MYD88 mutations is the production of IFNb (Ngo
et al., 2011), which is toxic to these tumors. The present study
revealed that IRF4 places a brake on IFNb expression by repres-
sing IRF7, allowing ABC DLBCLs with MYD88 mutations to
survive and proliferate. Additionally, IRF4 sustains ABC DLBCL
survival by transactivating CARD11 and potentiating NF-kB
signaling. IRF4 emerges from these studies as a central regula-
tory hub in ABC DLBCL, making it an attractive therapeutic
target. IRF4 and its regulatory partner SPIB were downregulated
by treatment of ABC DLBCL lines with lenalidomide, a drug that
has shown preferential activity against this lymphoma subtype
in early-phase clinical trials (Hernandez-Ilizaliturri et al., 2011).
Lenalidomide toxicity for ABC DLBCL was associated with
heightened IFNb production and diminished NF-kB activity.
Hence, lenalidomide toxicity in ABCDLBCL relies upon itsmodu-
lation of oncogenically activated signaling pathways, and there-
fore is an instance of ‘‘synthetic lethality’’ (Kaelin, 2005).
This study highlights the central role of IRF4-SPIB hetero-
dimers in ABC DLBCL biology, particularly in amplifying NF-kB
signaling while blocking type I interferon signaling. In addition,
IRF4 directly upregulates a large number of genes that distin-
guish ABC DLBCL from other lymphoma subtypes, many of
which may contribute to viability or other attributes of these
lymphoma cells. Remarkably, survival of ABC DLBCL cells
depended on a single amino acid in IRF4 that mediates its inter-
action with SPIB on composite EICE motifs. IRF4 is clearly
central to the action of lenalidomide in ABC DLBCL, since en-
forced overexpression of IRF4 blocked the toxic effect of this
drug, presumably by driving IRF4-SPIB interactions by mass
action. IRF4 is similarly downregulated by lenalidomide in
multiple myeloma (Li et al., 2011; Lopez-Girona et al., 2011;
Zhu et al., 2011). In both ABC DLBCL and multiple myeloma,
IRF4 levels are maintained by CRBN, a subunit of a ubiquitin
ligase complex. We discovered that CRBN also controls SPIB
levels in ABC DLBCL, which is not relevant to multiple myeloma,
as these cells do not express SPIB. Thalidomide, a chemically
related cousin of lenalidomide, physically interacts with CRBN
and blocks the ability of this ubiquitin ligase complex to autoubi-
quitinate (Ito et al., 2010). Further investigation is needed to
discern how this ubiquitin ligase might control IRF4 and SPIB
expression, apparently at the level of transcription.Cancer Cell 21, 723–737, June 12, 2012 ª2012 Elsevier Inc. 733
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Figure 7. Synergy between Lenalidomide and NF-kB Pathway Inhibitors in ABC DLBCL
(A) Western blot of the indicated proteins in OCI-Ly10 cells treated with lenalidomide (5 mM) alone or with MLN120B (10 mM), ibrutinib (5nM), or DMSO for the
indicated times.
(B) ISRE-driven luciferase activity in OCI-Ly10 cells treated with lenalidomide (5 mM) ± ibrutinib (5 nM) for the indicated times. Error bars show the SEM of
triplicates.
(C) IKK activity measured by an IkBa-luciferase reporter in TMD8 cells treated with ibrutinib at the indicated concentrations ± lenalidomide (1 mM) for 48 hr. Error
bars show the SEM of triplicates.
(D) Viability (MTS assay) of OCI-Ly10 treated with MLN120B at the indicated concentrations ± lenalidomide (1 mM) for 4 days relative to DMSO-treated cells. Error
bars show the SEM of triplicates.
(E) Viability (MTS assay) of DLBCL lines treated with ibrutinib, lenalidomide, or both for 4 days at the concentrations indicated. Error bars show the SEM of
triplicates.
(F) OCI-Ly10 ABC DLBCL cells were established as a subcutaneous tumor (average 80 mm3) in immunodeficient mice, and then treated daily for 20 days with
DMSO, lenalidomide (10 mg/kg), ibrutinib (3 mg/kg), or lenalidomide plus ibrutinib by intraperitoneal injection. Tumor progression was monitored as a function of
tumor volume. Error bars show the SEM of 5 mice per group.
See also Figure S6.
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Synthetic Lethal Therapy of ABC DLBCLOur findings provide a sound mechanistic basis for clinical
trials in ABC DLBCL that rationally combine lenalidomide with
other drugs that modulate NF-kB signaling. Drugs targeting
NF-kB hold promise in cancer therapy, despite some concerns
about long-term suppression of this pathway (Baud and Karin,
2009; Gupta et al., 2010). In ABC DLBCL, NF-kB activity relies
upon chronic active BCR signaling, which can be blocked by
several drugs that are currently in clinical trials, including ibrutinib
(targeting BTK) (Davis et al., 2010), fostamatinib (targeting SYK)
(Friedberg et al., 2009), and CAL-101 [targeting PI(3) kinase d]734 Cancer Cell 21, 723–737, June 12, 2012 ª2012 Elsevier Inc.(Herman et al., 2010; Hoellenriegel et al., 2011). Additionally,
NF-kB signaling can be inhibited by interfering with IkBa degra-
dation, which can be achieved with the proteasome inhibitor
bortezomib (Dunleavy et al., 2009) or the neddylation inhibitor
MLN4924 (Milhollen et al., 2010). As a single agent, the BTK
inhibitor ibrutinib is highly active against ABC DLBCL cells
in vitro (Davis et al., 2010), and is showing clinical activity in a
subset of patients with relapsed/refractory ABC DLBCL (L.M.S.,
unpublished data). We observed striking synergy between ibru-
tinib and lenalidomide in blocking IRF4 expression, increasing
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Figure 8. Exploiting Synthetic Lethality for
the Therapy of ABC DLBCL
Recurrent oncogenic mutations in ABC DLBCL
activate both the BCR and MYD88 pathways
to drive prosurvival NF-kB signaling. However,
MYD88 signaling also induces IFNb, which is
detrimental to ABC DLBCL survival. IRF4 and
SPIB lie at the nexus of both pathways, promoting
ABC DLBCL survival by repressing IRF7, thereby
blocking IFNb, and transactivating CARD11,
thereby increasing NF-kB signaling. NF-kB factors
transactivate IRF4, creating a positive feedback
oncogenic loop. Lenalidomide targets this circuitry
by downmodulating IRF4 and SPIB, thereby
increasing toxic IFNb secretion and decreasing
NF-kB activity.
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Synthetic Lethal Therapy of ABC DLBCLIFNb production, and killing ABC DLBCL cells in vitro and in vivo,
supporting clinical evaluation of this treatment regimen.
The effectiveness of this drug combination in ABC DLBCL
capitalizes on recurrent genetic alterations in ABC DLBCL in
two ways. First, the MYD88 L265P mutant promotes the
abnormal synthesis and secretion of IFNb. Second, mutations
in the BCR subunits CD79A and CD79B promote chronic active
BCR signaling, which activates NF-kBand induces IRF4, thereby
dampening the toxic type I interferon responsewhile augmenting
the prosurvival NF-kB response. Hence, these recurrent onco-
genic mutations in ABC DLBCL and the constitutive signaling
pathways that they engage place IRF4 in a central regulatory
position (Figure 8). Indeed, one reason that CD79B mutations
often coexist with the MYD88 L265P mutation in ABC DLBCL
tumors (Ngo et al., 2011) may be that the production of IRF4 in
response to chronic active BCR signaling is necessary for the
tumor to dampen the interferon response caused by the
MYD88 L265P mutation. The rational therapeutic combinations
proposed herein act in a synthetic lethal fashion to exploit this
IRF4 addiction.
EXPERIMENTAL PROCEDURES
(See Supplemental Experimental Procedures for details.)
Cell Culture and Constructs
Methods for cell culture, plasmid transfection, retroviral transduction, and
plasmid constructs were described previously (Lenz et al., 2008c; Ngo et al.,
2006; Shaffer et al., 2008).
Chromatin Immunoprecipitation
Chromatin immunoprecipitations (ChIP) were performed as described (Shaffer
et al., 2008). Such ChIP-enriched DNA was either used in region-specific
assessment of antibody binding by real-time PCR, or made into libraries for
ChIP sequencing on a Genome Analyzer II (GAII, Illumina, Inc.) according to
manufacturer’s recommendations. See Supplemental Experimental Proce-
dures for details.
Gene Expression: Q-RTPCR and Profiling
Unless otherwise described, Q-RTPCR was performed on cDNA as previously
described in Sciammas et al. (2006) and Shaffer et al. (2004, 2008), using pre-Cancer Cell 21, 723–7tested Assay-on-demand probe/primer sets from
Applied Biosystems or primers designed for use
with SYBR green using an ABI 7700 Taqman
machine for 40 cycles with an annealing tempera-
ture of 60C. Gene expression was normalized to
the expression of beta-2-microglobulin for all samples. Gene-expression
profiling was performed using two-color human Agilent 4x44K gene-
expression arrays, exactly as described by the manufacturer, comparing
signal from control cells (Cy3) and experimentally manipulated cells (Cy5).
Array elements were filtered for those meeting confidence thresholds for
spot size, architecture, and level above local background. These criteria are
a feature of the Agilent gene-expression software package for Agilent 4x44k
arrays.
Cell Viability—MTS—Assay
Cells were plated in triplicate at a density of 15,000 cells per well in 96-well
plates. Cell viability after indicated treatments was assayed by adding
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-
2H tetrazolium and an electron coupling reagent (phenazine methosulphate;
Promega), incubated for 3 hr and measured by the amount of 490 nm absor-
bance using a 96-well plate reader. The background was subtracted using
a media-only control.
NF-kB Reporter Assays
The assay for IkB kinase activity using the IkBalpha-photinus luciferase
reporter has been described (Lenz et al., 2008a), as has use of the IkB kinase
inhibitor (Lam et al., 2005). In addition, cell lines were created with an NF-kB
transcriptional reporter by transduction with lentiviral particles containing an
inducible NF-kB -responsive luciferase reporter construct (SA Biosciences)
and selected with puromycin. Luciferase activity was measured using the
Dual-Luciferase Reporter Assay System (Promega) on a Microtiter Plate
Luminometer (Dyn-Ex Technologies).
ISRE Reporter Assay
Cell lines were transduced with lentiviral particles containing an inducible
ISRE-responsive luciferase reporter construct (SA Biosciences) and selected
with puromycin. Luciferase activity was measured using the Dual-Luciferase
Reporter Assay System (Promega) on a Microtiter Plate Luminometer (Dyn-
Ex Technologies).
IFNb ELISA
Human IFNb was measured using ELISA kits from PBL InterferonSource. The
results were normalized to live cell numbers.
Tumor Model and Therapy Study
The xenograft tumor model of human ABC DLBCL lymphoma was established
by subcutaneous (s.c.) injection of cells into nonobese diabetic/severe
combined immunodeficient (NOD/SCID) mice (NCI-Frederick, Frederick,
MD). Tumor growth was monitored by measuring tumor size in two37, June 12, 2012 ª2012 Elsevier Inc. 735
Cancer Cell
Synthetic Lethal Therapy of ABC DLBCLorthogonal dimensions. See Supplemental Experimental Procedures
for details. All animal experiments were approved by the National Cancer
Institute Animal Care and Use Committee (NCI ACUC) and were performed
in accordance with NCI ACUC guidelines.ACCESSION NUMBERS
Gene-expression data has been deposited under accession numbers
GSE32456 and GSE33012. All ChIP-Seq data can be found under accession
SRA025850.SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, three tables, and Supplemental
Experimental Procedures and can be found with this article online at
doi:10.1016/j.ccr.2012.05.024.
ACKNOWLEDGMENTS
This research was supported by the Intramural Research Program of the NIH,
National Cancer Institute, Center for Cancer Research. We also thank Carla
Heise and Celgene for support. J.P. was supported by the UMD-NCI Partner-
ship for Cancer Technology. We thank M. Celeste Simon for the anti-SPIB
antibody. We wish to thank Kathleen Meyer for her assistance with GEO
submissions, and the members of the Staudt lab for their assistance and help-
ful discussions. J.J.B. and S.B. are employees and shareholders of Pharmacy-
clics, Inc.
Received: October 26, 2011
Revised: March 13, 2012
Accepted: May 22, 2012
Published: June 11, 2012
REFERENCES
Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A.,
Boldrick, J.C., Sabet, H., Tran, T., Yu, X., et al. (2000). Distinct types of diffuse
large B-cell lymphoma identified by gene expression profiling. Nature 403,
503–511.
Baud, V., and Karin, M. (2009). Is NF-kappaB a good target for cancer therapy?
Hopes and pitfalls. Nat. Rev. Drug Discov. 8, 33–40.
Brass, A.L., Kehrli, E., Eisenbeis, C.F., Storb, U., and Singh, H. (1996). Pip,
a lymphoid-restricted IRF, contains a regulatory domain that is important for
autoinhibition and ternary complex formation with the Ets factor PU.1.
Genes Dev. 10, 2335–2347.
Brass, A.L., Zhu, A.Q., and Singh, H. (1999). Assembly requirements of PU.1-
Pip (IRF-4) activator complexes: inhibiting function in vivo using fused dimers.
EMBO J. 18, 977–991.
Davis, R.E., Brown, K.D., Siebenlist, U., and Staudt, L.M. (2001). Constitutive
nuclear factor kB activity is required for survival of activated B cell-like diffuse
large B cell lymphoma cells. J. Exp. Med. 194, 1861–1874.
Davis, R.E., Ngo, V.N., Lenz, G., Tolar, P., Young, R.M., Romesser, P.B.,
Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010). Chronic active
B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463, 88–92.
Dunleavy, K., Pittaluga, S., Czuczman, M.S., Dave, S.S., Wright, G., Grant, N.,
Shovlin, M., Jaffe, E.S., Janik, J.E., Staudt, L.M., and Wilson, W.H. (2009).
Differential efficacy of bortezomib plus chemotherapy within molecular
subtypes of diffuse large B-cell lymphoma. Blood 113, 6069–6076.
Eisenbeis, C.F., Singh, H., and Storb, U. (1995). Pip, a novel IRF family
member, is a lymphoid-specific, PU.1-dependent transcriptional activator.
Genes Dev. 9, 1377–1387.
Escalante, C.R., Brass, A.L., Pongubala, J.M., Shatova, E., Shen, L., Singh, H.,
and Aggarwal, A.K. (2002a). Crystal structure of PU.1/IRF-4/DNA ternary
complex. Mol. Cell 10, 1097–1105.736 Cancer Cell 21, 723–737, June 12, 2012 ª2012 Elsevier Inc.Escalante, C.R., Shen, L., Escalante, M.C., Brass, A.L., Edwards, T.A., Singh,
H., and Aggarwal, A.K. (2002b). Crystallization and characterization of PU.1/
IRF-4/DNA ternary complex. J. Struct. Biol. 139, 55–59.
Friedberg, J.W., Sharman, J., Sweetenham, J., Johnston, P.B., Vose, J.M.,
Lacasce, A., Schaefer-Cutillo, J., De Vos, S., Sinha, R., Leonard, J.P., et al.
(2009). Inhibition of Syk with fostamatinib disodium has significant clinical
activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood
115, 2578–2585.
Greco, W.R., Park, H.S., and Rustum, Y.M. (1990). Application of a new
approach for the quantitation of drug synergism to the combination of cis-
diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer
Res. 50, 5318–5327.
Gupta, S.C., Sundaram, C., Reuter, S., and Aggarwal, B.B. (2010). Inhibiting
NF-kB activation by small molecules as a therapeutic strategy. Biochim.
Biophys. Acta 1799, 775–787.
Herman, S.E., Gordon, A.L., Wagner, A.J., Heerema, N.A., Zhao, W., Flynn,
J.M., Jones, J., Andritsos, L., Puri, K.D., Lannutti, B.J., et al. (2010).
Phosphatidylinositol 3-kinase-d inhibitor CAL-101 shows promising preclinical
activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic
cellular survival signals. Blood 116, 2078–2088.
Hernandez-Ilizaliturri, F.J., Deeb, G., Zinzani, P.L., Pileri, S.A., Malik, F.,
Macon, W.R., Goy, A., Witzig, T.E., and Czuczman, M.S. (2011). Higher
response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma
in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.
Cancer 117, 5058–5066.
Hoellenriegel, J., Meadows, S.A., Sivina, M., Wierda, W.G., Kantarjian, H.,
Keating, M.J., Giese, N., O’Brien, S., Yu, A., Miller, L.L., et al. (2011). The phos-
phoinositide 30-kinase delta inhibitor, CAL-101, inhibits B-cell receptor
signaling and chemokine networks in chronic lymphocytic leukemia. Blood
118, 3603–3612.
Honda, K., Yanai, H., Negishi, H., Asagiri, M., Sato, M., Mizutani, T., Shimada,
N., Ohba, Y., Takaoka, A., Yoshida, N., and Taniguchi, T. (2005). IRF-7 is the
master regulator of type-I interferon-dependent immune responses. Nature
434, 772–777.
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y.,
and Handa, H. (2010). Identification of a primary target of thalidomide terato-
genicity. Science 327, 1345–1350.
Kaelin, W.G., Jr. (2005). The concept of synthetic lethality in the context of anti-
cancer therapy. Nat. Rev. Cancer 5, 689–698.
Kanno, Y., Levi, B.Z., Tamura, T., and Ozato, K. (2005). Immune cell-specific
amplification of interferon signaling by the IRF-4/8-PU.1 complex.
J. Interferon Cytokine Res. 25, 770–779.
Klein, U., Casola, S., Cattoretti, G., Shen, Q., Lia, M., Mo, T., Ludwig, T.,
Rajewsky, K., and Dalla-Favera, R. (2006). Transcription factor IRF4 controls
plasma cell differentiation and class-switch recombination. Nat. Immunol. 7,
773–782.
Lam, L.T., Davis, R.E., Pierce, J., Hepperle, M., Xu, Y., Hottelet, M., Nong, Y.,
Wen, D., Adams, J., Dang, L., and Staudt, L.M. (2005). Small molecule inhibi-
tors of IkB kinase are selectively toxic for subgroups of diffuse large B-cell
lymphoma defined by gene expression profiling. Clin. Cancer Res. 11, 28–40.
Lam, L.T., Wright, G., Davis, R.E., Lenz, G., Farinha, P., Dang, L., Chan, J.W.,
Rosenwald, A., Gascoyne, R.D., and Staudt, L.M. (2008). Cooperative
signaling through the signal transducer and activator of transcription 3 and
nuclear factor-kB pathways in subtypes of diffuse large B-cell lymphoma.
Blood 111, 3701–3713.
Lehtonen, A., Veckman, V., Nikula, T., Lahesmaa, R., Kinnunen, L., Matikainen,
S., and Julkunen, I. (2005). Differential expression of IFN regulatory factor 4
gene in human monocyte-derived dendritic cells and macrophages.
J. Immunol. 175, 6570–6579.
Lenz, G., Nagel, I., Siebert, R., Roschke, A.V., Sanger, W., Wright, G.W., Dave,
S.S., Tan, B., Zhao, H., Rosenwald, A., et al. (2007). Aberrant immunoglobulin
class switch recombination and switch translocations in activated B cell-like
diffuse large B cell lymphoma. J. Exp. Med. 204, 633–643.
Cancer Cell
Synthetic Lethal Therapy of ABC DLBCLLenz, G., Davis, R.E., Ngo, V.N., Lam, L., George, T.C., Wright, G.W., Dave,
S.S., Zhao, H., Xu, W., Rosenwald, A., et al. (2008a). Oncogenic CARD11
mutations in human diffuse large B cell lymphoma. Science 319, 1676–1679.
Lenz, G., Wright, G., Dave, S.S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B.,
Goldschmidt, N., Iqbal, J., et al; Lymphoma/Leukemia Molecular Profiling
Project. (2008b). Stromal gene signatures in large-B-cell lymphomas.
N. Engl. J. Med. 359, 2313–2323.
Lenz, G., Wright, G.W., Emre, N.C., Kohlhammer, H., Dave, S.S., Davis, R.E.,
Carty, S., Lam, L.T., Shaffer, A.L., Xiao, W., et al. (2008c). Molecular subtypes
of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc. Natl.
Acad. Sci. USA 105, 13520–13525.
Li, S., Pal, R., Monaghan, S.A., Schafer, P., Ouyang, H., Mapara, M., Galson,
D.L., and Lentzsch, S. (2011). IMiD immunomodulatory compounds block
C/EBPb translation through eIF4E down-regulation resulting in inhibition of
MM. Blood 117, 5157–5165.
Lopez-Girona, A., Heintel, D., Zhang, L.H., Mendy, D., Gaidarova, S., Brady,
H., Bartlett, J.B., Schafer, P.H., Schreder, M., Bolomsky, A., et al. (2011).
Lenalidomide downregulates the cell survival factor, interferon regulatory
factor-4, providing a potential mechanistic link for predicting response. Br.
J. Haematol. 154, 325–336.
Marecki, S., and Fenton, M.J. (2000). PU.1/Interferon Regulatory Factor inter-
actions: mechanisms of transcriptional regulation. Cell Biochem. Biophys. 33,
127–148.
Marie´, I., Durbin, J.E., and Levy, D.E. (1998). Differential viral induction of
distinct interferon-alpha genes by positive feedback through interferon regula-
tory factor-7. EMBO J. 17, 6660–6669.
Milhollen, M.A., Traore, T., Adams-Duffy, J., Thomas,M.P., Berger, A.J., Dang,
L., Dick, L.R., Garnsey, J.J., Koenig, E., Langston, S.P., et al. (2010). MLN4924,
a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell
lymphoma models: rationale for treatment of NF-kB-dependent lymphoma.
Blood 116, 1515–1523.
Ngo, V.N., Davis, R.E., Lamy, L., Yu, X., Zhao, H., Lenz, G., Lam, L.T., Dave, S.,
Yang, L., Powell, J., and Staudt, L.M. (2006). A loss-of-function RNA interfer-
ence screen for molecular targets in cancer. Nature 441, 106–110.
Ngo, V.N., Young, R.M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.H.,
Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2011). Oncogenically active
MYD88 mutations in human lymphoma. Nature 470, 115–119.
Oshima, K., Yanase, N., Ibukiyama, C., Yamashina, A., Kayagaki, N., Yagita,
H., and Mizuguchi, J. (2001). Involvement of TRAIL/TRAIL-R interaction in
IFN-alpha-induced apoptosis of Daudi B lymphoma cells. Cytokine 14,
193–201.
Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, R.I.,
Gascoyne, R.D., Muller-Hermelink, H.K., Smeland, E.B., Giltnane, J.M., et al;
Lymphoma/LeukemiaMolecular Profiling Project. (2002). The use of molecular
profiling to predict survival after chemotherapy for diffuse large-B-cell
lymphoma. N. Engl. J. Med. 346, 1937–1947.
Rosenwald, A., Wright, G., Leroy, K., Yu, X., Gaulard, P., Gascoyne, R.D.,
Chan, W.C., Zhao, T., Haioun, C., Greiner, T.C., et al. (2003). Molecular diag-
nosis of primary mediastinal B cell lymphoma identifies a clinically favorable
subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.
J. Exp. Med. 198, 851–862.
Saito, M., Gao, J., Basso, K., Kitagawa, Y., Smith, P.M., Bhagat, G., Pernis, A.,
Pasqualucci, L., and Dalla-Favera, R. (2007). A signaling pathway mediatingdownregulation of BCL6 in germinal center B cells is blocked by BCL6 gene
alterations in B cell lymphoma. Cancer Cell 12, 280–292.
Sato, M., Hata, N., Asagiri, M., Nakaya, T., Taniguchi, T., and Tanaka, N.
(1998). Positive feedback regulation of type I IFN genes by the IFN-inducible
transcription factor IRF-7. FEBS Lett. 441, 106–110.
Schotte, R., Rissoan, M.C., Bendriss-Vermare, N., Bridon, J.M., Duhen, T.,
Weijer, K., Brie`re, F., and Spits, H. (2003). The transcription factor Spi-B is
expressed in plasmacytoid DC precursors and inhibits T-, B-, and NK-cell
development. Blood 101, 1015–1023.
Sciammas, R., Shaffer, A.L., Schatz, J.H., Zhao, H., Staudt, L.M., and Singh, H.
(2006). Graded expression of interferon regulatory factor-4 coordinates iso-
type switching with plasma cell differentiation. Immunity 25, 225–236.
Shaffer, A.L., Peng, A., and Schlissel, M.S. (1997). In vivo occupancy of the
kappa light chain enhancers in primary pro- and pre-B cells: a model for kappa
locus activation. Immunity 6, 131–143.
Shaffer, A.L., Shapiro-Shelef, M., Iwakoshi, N.N., Lee, A.-H., Qian, S.-B., Zhao,
H., Yu, X., Yang, L., Tan, B.K., Rosenwald, A., et al. (2004). XBP1, downstream
of Blimp-1, expands the secretory apparatus and other organelles, and
increases protein synthesis in plasma cell differentiation. Immunity 21, 81–93.
Shaffer, A.L., Wright, G., Yang, L., Powell, J., Ngo, V., Lamy, L., Lam, L.T.,
Davis, R.E., and Staudt, L.M. (2006). A library of gene expression signatures
to illuminate normal and pathological lymphoid biology. Immunol. Rev. 210,
67–85.
Shaffer, A.L., Emre, N.C., Lamy, L., Ngo, V.N., Wright, G., Xiao, W., Powell, J.,
Dave, S., Yu, X., Zhao, H., et al. (2008). IRF4 addiction in multiple myeloma.
Nature 454, 226–231.
Shaffer, A.L., Emre, N.C., Romesser, P.B., and Staudt, L.M. (2009). IRF4:
Immunity. Malignancy! Therapy? Clin. Cancer Res. 15, 2954–2961.
Stark, G.R., Kerr, I.M., Williams, B.R., Silverman, R.H., and Schreiber, R.D.
(1998). How cells respond to interferons. Annu. Rev. Biochem. 67, 227–264.
Tamura, T., Tailor, P., Yamaoka, K., Kong, H.J., Tsujimura, H., O’Shea, J.J.,
Singh, H., and Ozato, K. (2005). IFN regulatory factor-4 and -8 govern dendritic
cell subset development and their functional diversity. J. Immunol. 174, 2573–
2581.
Thome, M. (2004). CARMA1, BCL-10 and MALT1 in lymphocyte development
and activation. Nat. Rev. Immunol. 4, 348–359.
Thome, M., Charton, J.E., Pelzer, C., and Hailfinger, S. (2010). Antigen
receptor signaling to NF-kB via CARMA1, BCL10, and MALT1. Cold Spring
Harb. Perspect. Biol. 2, a003004.
Ucur, E., Mattern, J., Wenger, T., Okouoyo, S., Schroth, A., Debatin, K.M., and
Herr, I. (2003). Induction of apoptosis in experimental humanB cell lymphomas
by conditional TRAIL-expressing T cells. Br. J. Cancer 89, 2155–2162.
Wright, G., Tan, B., Rosenwald, A., Hurt, E.H., Wiestner, A., and Staudt, L.M.
(2003). A gene expression-based method to diagnose clinically distinct
subgroups of diffuse large B cell lymphoma. Proc. Natl. Acad. Sci. USA 100,
9991–9996.
Zhu, Y.X., Braggio, E., Shi, C.X., Bruins, L.A., Schmidt, J.E., Van Wier, S.,
Chang, X.B., Bjorklund, C.C., Fonseca, R., Bergsagel, P.L., et al. (2011).
Cereblon expression is required for the antimyeloma activity of lenalidomide
and pomalidomide. Blood 118, 4771–4779.Cancer Cell 21, 723–737, June 12, 2012 ª2012 Elsevier Inc. 737
